USC
ACMG Statement Says Preimplantation Polygenic Risk Testing 'Not Appropriate for Clinical Use' Yet
Overall, the organization remains skeptical of the clinical implementation of PRS testing, pointing to limitations of the tests and a lack of evidence for their clinical utility.
The FDA's approval of Novartis' Pluvicto and the imaging agent Locametz for PSMA-positive mCRPC has implications for cancer centers and other drugmakers in the radiopharmaceutical space.
USC Opens Phase II Trial of Ambrx's ARX788 for HER2-Positive Breast Cancer
The trial will evaluate metastatic, pretreated breast cancer patients' overall response rates on the HER2-directed antibody-drug conjugate.
Higher Early-Onset Cancer Risk Among Minorities Spurs Hunt for Genetic, Environmental Factors
Premium
USC researchers are sequencing Black, Latino, and Asian families in California and plan to study environmental causes for why they are more likely to inherit early-onset cancers.
Epic Sciences, USC Michelson Center Sign Licensing Agreement for Liquid Biopsy Research
Epic will access the center's liquid biopsy samples and expand its platform to in-depth characterization of cell-free fractions and circulating tumor cells.